169545-27-1
中文名稱
N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN
英文名稱
IRL-2500
CAS
169545-27-1
分子式
C36H35N3O4
分子量
573.68
MOL 文件
169545-27-1.mol
更新日期
2026/05/28 12:19:26
169545-27-1 結(jié)構(gòu)式
基本信息
中文別名
T15596化合物 T15596
化合物IRL 2500
(S)-2-((R)-3-([1,1'-聯(lián)苯]-4-基)-2-(N,3,5-三甲基苯甲酰胺基)丙酰胺基)-3-(1H-吲哚-3-基)丙酸
英文別名
IRL-2500L-Tryptophan, 3-[1,1'-biphenyl]-4-yl-N-(3,5-dimethylbenzoyl)-N-methyl-D-alanyl-
N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN
物理化學(xué)性質(zhì)
沸點(diǎn)893.7±65.0 °C(Predicted)
密度1.246±0.06 g/cm3(Predicted)
儲(chǔ)存條件Keep in dark place,Sealed in dry,Store in freezer, under -20°C
溶解度Soluble to 100 mM in 1eq. NaOH
酸度系數(shù)(pKa)3.34±0.10(Predicted)
形態(tài)粉末
顏色White to light yellow
N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-103460 | N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500 | 169545-27-1 | 1 mg | 448元 |
| 2026/06/05 | HY-103460 | N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500 | 169545-27-1 | 5mg | 1215元 |
| 2026/06/05 | HY-103460 | N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500 | 169545-27-1 | 10 mM * 1 mLin DMSO | 1533元 |
常見問(wèn)題列表
生物活性
IRL 2500 是一種有效的內(nèi)皮素受體 (Endothelin receptor) 拮抗劑，其 ETB 和 ETA 受體的 IC50 值分別為 1.3 和 94 nM。 IRL 2500 在體內(nèi)抑制 ETB 受體介導(dǎo)的血壓升高和腎血管阻力。靶點(diǎn)
|
ET B 1.3 nM (IC 50 ) |
ET A 94 nM (IC 50 ) |
體內(nèi)研究
IRL 2500 (intravenous?injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat. IRL 2500 (intravenous?injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists.